ProMIS Neurosciences

PMN50

Penny Stock

$0.98arrow_drop_up1.56%$0.01

Penny Stock

PMN50

$0.98

arrow_drop_up1.56%$0.01

Penny Stock

Performance History

Key Stats
Open	$0.98
Prev. Close	$0.99
EPS	-0.54
Dividend	Non-Dividend
Next Earnings Date	-
Dividend Yield %	-
Market Cap	$29.28M
PE Ratio	-

	LOW	HIGH
Day Range	0.94	1.04
52 Week Range	0.94	3.10

Ratios

Revenue	-



EBITDA Margin %	-

EPS	-0.54

Score Breakdown

Welcome to Stocklytics

Don't miss out on the opportunity to stay ahead in the ever-changing world of finance.

Analyst Forecast

Period: Next 12 Months

•

Analyst Ratings

•

About ProMIS Neurosciences (PMN)

ProMIS Neurosciences, Inc. (PMN) is a biotechnology company focused on discovering and developing precision medicine therapeutics for neurodegenerative diseases, with a particular emphasis on Alzheimer's disease (AD) and amyotrophic lateral sclerosis (ALS). The company's proprietary discovery platform utilizes its unique understanding of misfolded proteins to identify therapeutic targets that are specifically linked to these diseases. By targeting the toxic oligomers of misfolded proteins, ProMIS aims to develop highly selective antibody-based therapies that can halt the progression of neurodegeneration and ultimately improve patient outcomes.

One of ProMIS' key innovations is its use of computational algorithms to predict the specific regions of misfolded proteins that are likely to be toxic and targetable by therapeutic antibodies. This approach enables the company to design and develop highly selective antibodies that bind exclusively to these toxic species, while avoiding binding to harmless forms of the protein. This level of specificity is crucial for achieving therapeutic efficacy while minimizing the risk of unwanted side effects.

Websitecall_made

Sector: Healthcare
Industry: Biotechnology
CEO: Dr. Gail M. Farfel Ph.D.
Headquarters: Toronto
Employees: 6
Exchange: NASDAQ

Keep an eye on ProMIS Neurosciences

Adding the right stocks to your watchlist can provide valuable insights and opportunities for strategic decision-making.

Frequently Asked Questions

help

What is ProMIS Neurosciences's (PMN) price per share?

The current price per share for ProMIS Neurosciences (PMN) is $0.98. The stock has seen a price change of $0.02 recently, indicating a 1.56% change. This reflects the stock's recent market performance and investor sentiment.

help

What is the 52-week high and low for ProMIS Neurosciences (PMN)?

For ProMIS Neurosciences (PMN), the 52-week high is $3.1, which is 216.33% from the current price. The 52-week low is $0.94, the current price is 3.7% above the 52-week low. This gives investors an insight into the stock's volatility and price range over the past year.

help

Is ProMIS Neurosciences (PMN) a growth stock?

ProMIS Neurosciences (PMN) has shown an average price growth of -6.65% over the past three years. It has received a score of 6 out of 100 based on the Stocklytics formula. The interpretation of this score in terms of classifying ProMIS Neurosciences as a growth stock may vary, considering it is one of many factors investors might evaluate, including market trends, financial performance, and future prospects of the company.

help

What is ProMIS Neurosciences (PMN) stock price performance year to date (YTD)?

As of the latest data, ProMIS Neurosciences (PMN) has a year-to-date price change of -29.48%. Over the past month, the stock has experienced a price change of -5.77%. Over the last three months, the change has been -21.6%. Over the past six months, the figure is -51%.

help

Is ProMIS Neurosciences (PMN) a profitable company?

ProMIS Neurosciences (PMN) has a net income of -$17.51M, which represents the company's total earnings after all expenses have been deducted from revenues. The gross margin of indicates the percentage of revenue that exceeds the cost of goods sold, and the operating margin of 0% reflects the percentage of revenue remaining after covering variable production costs, highlighting the efficiency of the company's core operations. Total revenue stands at , although specific revenue growth data is currently not available. Operating income is noted at -$18.9M. Furthermore, the EBITDA is -$11.15M.

help

What is the market capitalization of ProMIS Neurosciences (PMN)?

ProMIS Neurosciences (PMN) has a market capitalization of $29.29M. The average daily trading volume is 1.01, indicating the stock's liquidity and investor engagement.